ARTELO BIOSCIENCES, INC.

Profile

Company Names

ARTELO BIOSCIENCES, INC.

Addresses

505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA 92075

505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA 92075

888 PROSPECT STREET, SUITE 210, LA JOLLA, CA 92037

888 PROSPECT STREET, SUITE 210, LA JOLLA, CA 92037

Phone Numbers

858-925-7049
760-943-1689
760 943 1689

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY, OTHER HEALTH CARE

Year Incorporated:

> 5 years ago

State Incorporated:

NEVADA

Total Amount Raised:

$33,246,326.00

Number of Funding Rounds:

13
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
13
2026-03-27 
$10,996,903.00 
$10,996,903.00 
$0.00 
Equity 
12
2026-03-20 
$315,000.00 
$315,000.00 
$0.00 
Debt 
11
2026-03-12 
$237,300.00 
$237,300.00 
$0.00 
Debt 
10
2026-01-30 
$500,000.00 
$50,500,000.00 
$50,000,000.00 
Equity 
9
2025-10-28 
$3,718,121.00 
$3,718,121.00 
$0.00 
Debt 
8
2025-08-05 
$9,475,000.00 
$9,475,000.00 
$0.00 
Equity 
7
2025-06-26 
$1,425,000.00 
$1,425,000.00 
$0.00 
Equity 
6
2022-05-13 
$96,972.00 
$20,096,972.00 
$20,000,000.00 
Equity 
5
2020-05-04 
$55,000.00 
$55,000.00 
$0.00 
Equity 
4
2019-04-25 
$857,430.00 
$1,950,000.00 
$1,092,570.00 
Equity 
3
2019-01-08 
$4,192,990.00 
$10,000,000.00 
$5,807,010.00 
Equity 
2
2018-07-31 
$525,824.00 
$1,125,000.00 
$599,176.00 
Equity 
1
2018-03-23 
$850,786.00 
$975,000.00 
$124,214.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
JOHN 
W. 
BECK 
DIRECTOR
DOUGLAS 
 
BLAYNEY 
DIRECTOR
R. 
MARTIN 
EMANUELE 
DIRECTOR
GEORGIA 
 
ERBEZ 
DIRECTOR
TAMARA 
A. 
FAVORITO 
DIRECTOR
GREGORY 
 
GORGAS 
EXECUTIVE OFFICER, DIRECTOR
GREGORY 
D. 
GORGAS 
EXECUTIVE OFFICER, DIRECTOR
CONNIE 
 
MATSUI 
DIRECTOR
PETER 
 
O-BRIEN 
EXECUTIVE OFFICER, DIRECTOR
GREGORY 
R. 
REYES 
DIRECTOR
TAMARA 
A. 
SEYMOUR 
DIRECTOR
MARK 
 
SPRING 
EXECUTIVE OFFICER, DIRECTOR
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2026-03-27 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2026-03-20 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2026-03-12 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2026-03-12 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2026-01-30 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2025-10-28 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2025-08-05 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2025-06-26 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2022-05-13 
D
BIOTECHNOLOGY 
SERVICES-BUSINESS SERVICES, NEC [7389] 
DECLINE TO DISCLOSE 
Equity 
2020-05-04 
D
OTHER HEALTH CARE 
SERVICES-BUSINESS SERVICES, NEC [7389] 
DECLINE TO DISCLOSE 
Equity 
2019-01-08 
D
OTHER HEALTH CARE 
SERVICES-BUSINESS SERVICES, NEC [7389] 
DECLINE TO DISCLOSE 
Equity 
2019-04-25 
D
OTHER HEALTH CARE 
SERVICES-BUSINESS SERVICES, NEC [7389] 
DECLINE TO DISCLOSE 
Equity 
2018-07-31 
D
OTHER HEALTH CARE 
SERVICES-BUSINESS SERVICES, NEC [7389] 
DECLINE TO DISCLOSE 
Equity 
2018-03-23 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
H.C. WAINWRIGHT + CO., LLC
375